Medivir appoints vp for r&d projects

Charlotte Edenius takes up newly created position

Medivir, a Swedish research-based specialist pharmaceutical company focused on infectious diseases, has appointed Charlotte Edenius to the new position of vice president, research & development projects.

Edenius holds a medical degree and has a PhD from the Karolinska Institute. She joined Medivir this month from Swedish pharmaceutical company Orexo, where she was senior vice president and chief scientific officer.

Prior to this, Edenius was vice president and chief scientific officer of Biolipox from 2001–2007 and held various executive positions in experimental medicine, Clinical R&D at AstraZeneca in Sweden.

Medivir’s key pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical development for Hepatitis C and is partnered with Tibotec Pharmaceuticals.

You may also like

Research & Development

Medivir partners with GVK BIO to optimise R&D

Company reorganises its discovery and research operations and focuses on key areas of oncology and infectious diseases
Research & Development

Medivir and Cancer Research Technology link up to develop new cancer drugs

Will conduct a two-year research programme to develop small molecules targeting the ADAM8 protein
Research & Development

Medivir to develop new drugs for bacterial infections

Swedish University of Agricultural Sciences will receive a fee for research services
Research & Development

Medivir signs dengue virus deal with Janssen

Strengthens presence in infectious diseases
Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development

EVerZom and GENFIT partner for research collaboration for liver failure candidate EViv

The agreement will support EVerZom’s dynamic development strategy and follows the recent announcement of a €10m financing round aimed at accelerating its clinical and partnering roadmap
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
Subscribe now